| scholarly article | Q13442814 |
| P50 | author | Xiaoni Kong | Q90152378 |
| P2093 | author name string | Chang Yu | |
| Hailong Wu | |||
| Qiang Xia | |||
| Jie Cai | |||
| Han Guo | |||
| Yueqiu Gao | |||
| Xuehua Sun | |||
| Hongting Huang | |||
| Xiaoye Qu | |||
| P2860 | cites work | UCK2 upregulation might serve as an indicator of unfavorable prognosis of hepatocellular carcinoma | Q57284291 |
| Nonmetabolic functions of metabolic enzymes in cancer development | Q58113124 | ||
| Enzymes of the de novo and salvage pathways for pyrimidine biosynthesis in normal colon, colon carcinoma, and xenografts | Q72388837 | ||
| Epidermal growth factor receptor expression and gene copy number in conventional hepatocellular carcinoma | Q80522943 | ||
| Epidemiology of hepatocellular carcinoma | Q86100014 | ||
| Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis | Q21144594 | ||
| Review of aerobic glycolysis and its key enzymes - new targets for lung cancer therapy | Q26798253 | ||
| Serine and glycine metabolism in cancer | Q26863700 | ||
| Prognostic biomarkers for prediction of recurrence of hepatocellular carcinoma: current status and future prospects | Q27021265 | ||
| Phosphorylation of uridine and cytidine nucleoside analogs by two human uridine-cytidine kinases | Q28117835 | ||
| Structural basis for the specificity, catalysis, and regulation of human uridine-cytidine kinase | Q28118733 | ||
| Metabolic reprogramming: a cancer hallmark even warburg did not anticipate | Q29617612 | ||
| A New Bliss Independence Model to Analyze Drug Combination Data | Q30747693 | ||
| ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics | Q33601653 | ||
| Structure of human uridine-cytidine kinase 2 determined by SIRAS using a rotating-anode X-ray generator and a single samarium derivative | Q33985353 | ||
| Epidermal Growth Factor Receptor in Glioma: Signal Transduction, Neuropathology, Imaging, and Radioresistance | Q34105339 | ||
| Patient-derived xenograft models: an emerging platform for translational cancer research | Q34205518 | ||
| EGFR and cancer prognosis | Q34399312 | ||
| Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer | Q34557318 | ||
| The molecular determinants of de novo nucleotide biosynthesis in cancer cells | Q34939794 | ||
| Elevated free fatty acid uptake via CD36 promotes epithelial-mesenchymal transition in hepatocellular carcinoma | Q36109796 | ||
| Pyrimidine pathways in health and disease | Q36228595 | ||
| Increased lipogenesis in cancer cells: new players, novel targets. | Q36508459 | ||
| Expression and clinical significance of erb-B receptor family in hepatocellular carcinoma | Q36622264 | ||
| Phase II study of TAS-106 in patients with platinum-failure recurrent or metastatic head and neck cancer and nasopharyngeal cancer. | Q36977432 | ||
| Molecular targeted therapies in hepatocellular carcinoma | Q37003665 | ||
| Methylglyoxal, a glycolysis side-product, induces Hsp90 glycation and YAP-mediated tumor growth and metastasis. | Q37368367 | ||
| Novel patient-derived xenograft and cell line models for therapeutic testing of pediatric liver cancer | Q38775165 | ||
| Proteomic analysis of the epidermal growth factor receptor (EGFR) interactome and post-translational modifications associated with receptor endocytosis in response to EGF and stress | Q38998504 | ||
| Akt-RSK-S6 kinase signaling networks activated by oncogenic receptor tyrosine kinases | Q39663675 | ||
| Role of epidermal growth factor receptor degradation in gemcitabine-mediated cytotoxicity. | Q40200594 | ||
| Sequence-, time- and dose-dependent synergism of methotrexate and 6-mercaptopurine in malignant human T-lymphoblasts | Q41247469 | ||
| Serine mutations that abrogate ligand-induced ubiquitination and internalization of the EGF receptor do not affect c-Cbl association with the receptor | Q42833869 | ||
| Sensitivity of human cancer cells to the new anticancer ribo-nucleoside TAS-106 is correlated with expression of uridine-cytidine kinase 2. | Q44083591 | ||
| Prognostic value of 1p, 19q, 9p, 10q, and EGFR-FISH analyses in recurrent oligodendrogliomas | Q44768519 | ||
| Expression of epidermal growth factor receptor in gastric carcinomas | Q44797497 | ||
| Metabolic targets for cancer therapy | Q46213230 | ||
| Structural and Biochemical Studies on the Reaction Mechanism of Uridine-Cytidine Kinase. | Q53462281 | ||
| The pivotal role of uridine-cytidine kinases in pyrimidine metabolism and activation of cytotoxic nucleoside analogues in neuroblastoma. | Q54192266 | ||
| Investigation of ErbB1 and ErbB2 expression for therapeutic targeting in primary liver tumours | Q57003964 | ||
| P433 | issue | 12 | |
| P304 | page(s) | 103 | |
| P577 | publication date | 2020-12-04 | |
| P1433 | published in | Oncogenesis | Q27724395 |
| P1476 | title | Non-metabolic role of UCK2 links EGFR-AKT pathway activation to metastasis enhancement in hepatocellular carcinoma | |
| P478 | volume | 9 |
Search more.